The orphan drug mechlorethamine gel was approved by the US Food and Drug Administration for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received previous skin-directed therapy. It is the first and only approved topical formulation of mechlorethamine. Mechlorethamine, also known as nitrogen mustard, is an alkylating agent that inhibits rapidly proliferating cells. It is applied topically once a day and dries on the skin.
Click on the PDF icon at the top of this introduction to read the full article.